Compare
Propanc Biopharma, Inc. vs Galectin Therapeutics Inc vs Marker Therapeutics, Inc. vs Genelux Corp
| Latest fiscal year | Propanc Biopharma, Inc. PPCB | Galectin Therapeutics Inc GALT | Marker Therapeutics, Inc. MRKR | Genelux Corp GNLX |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $3.55M | $8.0K |
| Revenue growth (YoY) | n/a | n/a | -46.2% | 0.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | -363.5% | n/m |
| Net margin | n/a | n/a | -343.0% | n/m |
| Net income | -$58.92M | -$30.84M | -$12.16M | -$32.15M |
| EPS (Diluted) | -$14.85 | -$0.48 | -$0.79 | -$0.86 |
| Operating cash flow | -$405.2K | -$23.88M | -$12.01M | -$25.27M |
| Free cash flow | n/a | n/a | n/a | -$26.37M |
| Cash & equivalents | n/a | $17.72M | $16.07M | $5.33M |
| Total assets | $19.63M | $19.53M | $19.07M | $19.03M |
| Total liabilities | $5.73M | $145.73M | $2.27M | $7.48M |
| Shareholders' equity | $13.91M | -$127.92M | $16.80M | $11.54M |
| Return on year-end equity | -423.7% | n/a | -72.4% | -278.5% |
| Shares outstanding | 11.61M | 65.20M | 16.70M | 38.14M |
Revenue, most recent five fiscal years
| Fiscal year | Propanc Biopharma, Inc. | Galectin Therapeutics Inc | Marker Therapeutics, Inc. | Genelux Corp |
|---|---|---|---|---|
| Latest | n/a | n/a | $3.55M Ended 2025-12-31 | $8.0K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $6.59M Ended 2024-12-31 | $8.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $3.31M Ended 2023-12-31 | $170.0K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $3.51M Ended 2022-12-31 | $11.07M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $1.24M Ended 2021-12-31 | n/a |